Newsroom

SAN FRANCISCO--(BUSINESS WIRE)--GC AI, the legal intelligence platform built for in-house legal teams, has partnered with Docusign, the Intelligent Agreement Management company, to help legal and business teams find and analyze their contracts and deliver insights and answers faster. With this key integration, legal teams can analyze their entire Docusign contracts portfolio with GC AI’s Contract Intelligence feature, and support their business faster, with the information and context they need...

CHICAGO--(BUSINESS WIRE)--Kemper Corporation (NYSE: KMPR) announced today that its Board of Directors has declared a quarterly dividend of $0.32 per share. The dividend is payable on December 2, 2026, to Kemper’s shareholders of record as of November 16, 2026. About Kemper The Kemper family of companies is one of the nation's leading specialized insurers. With approximately $12 billion in assets, Kemper is improving the world of insurance by providing affordable and easy-to-use personalized sol...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global do setor de oncologia, anunciou hoje que a Food and Drug Administration (FDA) dos EUA aceitou e concedeu "análise prioritária" (Priority Review) ao pedido suplementar de novo medicamento (sNDA, na sigla em inglês) para o BRUKINSA® (zanubrutinibe) em combinação com rituximabe, destinado ao tratamento de pacientes adultos com linfoma de células do manto (LCM) não tratado previam...

NEW YORK--(BUSINESS WIRE)--KBRA assigns a long-term rating of AAA to the State of Connecticut Special Tax Obligation Bonds, Transportation Infrastructure Purposes, 2026 Series B. KBRA additionally affirms the long-term rating of AAA for the State's outstanding Special Tax Obligation Bonds, Transportation Infrastructure Purposes. The rating Outlook is Stable. Key Credit Considerations The rating actions reflect the following key credit considerations: Credit Positives Diverse pledged revenue sou...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), un'azienda farmaceutica oncologica globale, oggi ha annunciato che la Food and Drug Administration (FDA) statunitense ha accettato e concesso la Priority Review (revisione prioritaria) alla sNDA (Supplemental New Drug Application, Domanda Supplementare di Nuovo Farmaco) per BRUKINSA® (zanubrutinib) in combinazione con rituximab per il trattamento di pazienti adulti affetti da linfoma mantellare (M...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), una compañía oncológica de alcance global, anunció hoy que la U.S. Food and Drug Administration (FDA) ha aceptado y concedido una revisión prioritaria a la solicitud complementaria de nuevo fármaco (sNDA) para BRUKINSA® (zanubrutinib) en combinación con rituximab para el tratamiento de pacientes adultos con linfoma de células del manto (LCM) no tratado previamente. La solicitud está respaldada por...

ATLANTA--(BUSINESS WIRE)--CareValidate, the compliance and clinical infrastructure behind some of the fastest-growing telehealth brands in the country, is launching same-day prescription delivery in Houston. Telehealth businesses on the CareValidate platform can now offer eligible patients home delivery within hours instead of waiting days for traditional mail-order fulfillment. The launch starts with eligible compounded GLP-1 medications and the antinausea medication, ondansetron. CareValidate...

ISLAMORADA, Fla.--(BUSINESS WIRE)--Bastion Fiduciary, a fee-only Registered Investment Advisor (RIA) acquires SJL Financial, fee-only financial planning firm founded by Sam Lewis....

SASKATOON, Saskatchewan--(BUSINESS WIRE)--Cameco Corporation (TSX : CCO ; NYSE : CCJ) annonce aujourd’hui avoir déposé, sur une base volontaire, un rapport technique portant sur l’exploitation de McArthur River en vertu du Règlement 43-101 sur l'information concernant les projets miniers (« Règlement 43-101 »). Ce rapport technique est déposé afin de fournir de l’information à jour concernant l’exploitation de McArthur River, et non par suite d’un changement des réserves minérales ou des ressou...

تشنغدو، الصين--(BUSINESS WIRE)--تقوم شركة Chengdu Zenitar Biomedical Technology Co., Ltd. ‏(Zenitar) بتطوير فلونولتينيب ماليات (FM)، وهو مثبط JAK2/FLT3/CDK6 عن طريق الفم من الفئة الأولى لعلاج الأورام التكاثرية النخاعية (MPNs)، بما في ذلك تليف النخاع العظمي (MF) وكثرة الحمر الحقيقية (PV).أطلقت شركة Zenitar الدراسة FM-MF-02 المعشاة من المرحلة الثانية (NCT07750574) في الولايات المتحدة وكندا والبرازيل، لتحديد جرعة المرحلة الثالثة لمرضى تليف النخاع العظمي (MF) الذين لم يتلقوا مثبطات JAK من قبل (JAKi-...